Cited by 132Cholesterol and Lipid MetabolismLipid metabolism and disordersLipoproteins and Cardiovascular Health

Liver X receptors (LXR) as therapeutic targets in dyslipidemia

Open access
Bełtowski, Jerzy·2008·Cardiovascular Therapeutics

Abstract

Liver X receptors (LXR) α and β belong to a family of nuclear receptors which form heterodimers with the retinoid X receptor (RXR) and, upon ligand binding, stimulate the expression of target genes. LXR were initially described as orphan receptors and later oxidized cholesterol derivatives (oxysterols) were identified as their natural ligands. In addition, several synthetic LXR agonists such as T0901317 and GW3965 were synthesized. Oxysterols are formed in amounts proportional to cholesterol content in the cell and therefore LXR operate as cholesterol sensors which protect from cholesterol overload by inhibiting intestinal cholesterol absorption, stimulating cholesterol efflux from cells to high‐density lipoproteins (HDL), its transport to the liver, conversion to bile acids, and biliary excretion. In addition, LXR agonists activate fatty acid synthesis by stimulating the expression of a lipogenic transcription factor, sterol regulatory element‐binding protein‐1c (SREBP‐1c), leading to the elevation of plasma triglycerides and liver steatosis. Lipogenic effect seems is the most important negative feature of LXR agonists considered as potential hypolidemic drugs. Some of currently used drugs also affect LXR signaling. For example, statins may impair LXR signaling by inhibiting oxysterol synthesis, whereas fibrates and thiazolidinediones increase LXR expression and activity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1755-5922.2008.00062.x

Cites

141 of 141 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LXR panmodulators are linked to side effects such as hyperlipidemia and liver steatosis.

    “Whilst LXR activation seems to have the potential to ameliorate liver fibrosis and despite promising results in animal studies, LXR panmodulators were linked to side effects such as hyperlipidemia and liver steatosis.”

    From Nuclear receptors in liver fibrosis (2021) · cites this paper as [164]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Wang MD, Kiss RS, Franklin V, McBride HM, Whitman SC, Marcel YL. Different intracellular trafficking of LDL- and acetylated LDL-derived cholesterol lead to distinct reverse cholesterol transport mechanisms. J Lipid Res 2007;48:633-645.

Cited by

Sorted by citations

Authors
Bełtowski, J.
Affiliations
Medical University of Lublin (PL)
Corresponding author
Bełtowski, Jerzy
Venue
Cardiovascular Therapeutics
Publisher
Wiley
Published
2008-11-11
Volume
26
Issue
4
Pages
297-316
ISSN
  • 1755-5914 (ISSN-L)
  • 1755-5922
OpenAlex
W2034339368
Cited by
132
References
141
Citations by year
2026: 4 · 2025: 6 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 8 · 2020: 8 · 2019: 11 · 2018: 11 · 2017: 10 · 2016: 9 · 2015: 6 · 2014: 6 · 2013: 16 · 2012: 9
FWCI
0.80
Type
journal article
Language
en
Open access
Locations
  • Cardiovascular Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
Keywords
liver X receptor, LXR agonists, dyslipidemia, oxysterols, cholesterol sensing, intestinal cholesterol absorption, cholesterol efflux, bile acid synthesis, SREBP-1c, fatty acid synthesis, hepatic steatosis, triglycerides, statins, fibrates, thiazolidinediones, lipid-lowering drugs, retinoid X receptor, nuclear receptors
MeSH terms
Liver X Receptors, Benzenesulfonamides, Animals, Benzoates, Benzylamines, Cholesterol, DNA-Binding Proteins, Fluorocarbons, Hydrocarbons, Fluorinated, Sulfonamides, Receptors, Cytoplasmic and Nuclear, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Orphan Nuclear Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review